Presentation is loading. Please wait.

Presentation is loading. Please wait.

Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA.

Published byVincent Parker Modified over 9 years ago

Similar presentations

Presentation on theme: "Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA."— Presentation transcript:

1 Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA

2 Question 1 1. Based on the data presented and in your scientific and clinical opinion, do the benefits of gemifloxacin therapy outweigh the risks for the proposed indications of: (a) Community acquired pneumonia (b) Acute bacterial exacerbation of chronic bronchitis Please include as part of your discussion: the clinical and microbiologic benefits of gemifloxacin the significance of the rash, particularly as it relates to the likelihood of more severe dermatological manifestations with broader use and the likelihood of cross-sensitization to other fluoroquinolones The hepatic toxicity profile of the drug

3 Question 2 2. If the answer to question (1a/1b) is yes, please discuss the types of information that should be provided to physicians and patients. Please focus on the elements outlined in question 1 as well as any other issues you believe relevant. Please include as part of this discussion any caveats as to how and to whom the drug should be administered. For any risk communication/management strategy that may be appropriate, please comment on how practical and/or effective such strategies may be.

4 Question 3 3. If the answer to (1a/1b) is no, please recommend what additional studies or information should be obtained for (a) Community acquired pneumonia (b) Acute bacterial exacerbation of chronic bronchitis

Download ppt "Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA."

Similar presentations

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
Development of the Consumer Professional Partnership Program (CPPP) Thilo Kroll NRH CHDR Steve Towle SCI Network RRTC on SCI: Promoting Health and Preventing.

Development of the Consumer Professional Partnership Program (CPPP) Thilo Kroll NRH CHDR Steve Towle SCI Network RRTC on SCI: Promoting Health and Preventing.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.

Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Edward P. Sloan, MD, MPH ACEP Clinical Policy Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department.

Edward P. Sloan, MD, MPH ACEP Clinical Policy Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department.
G aps, challenges and opportunities Theo Verheij University Medical Center Utrecht Lower Respiratory Tract Infections in Primary Care.

G aps, challenges and opportunities Theo Verheij University Medical Center Utrecht Lower Respiratory Tract Infections in Primary Care.
FDA Perspective Sally Loewke, M.D. Acting Division Director

FDA Perspective Sally Loewke, M.D. Acting Division Director
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Macrolide-Resistant Streptococcus pneumoniae: What is the Public Health Impact? John H. Powers, M.D. Lead Medical Officer Antimicrobial Drug Development.

Macrolide-Resistant Streptococcus pneumoniae: What is the Public Health Impact? John H. Powers, M.D. Lead Medical Officer Antimicrobial Drug Development.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.

Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Presented by Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmology Drug Products ODEV, CDER, FDA at the Arthritis Advisory.

Presented by Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmology Drug Products ODEV, CDER, FDA at the Arthritis Advisory.
Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance 526-6876 August 22, 2003.

INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Similar presentations

Ads by Google